Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Capital Reinvestment Ratio
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Capital Reinvestment Ratio of 0.24x as of March 2023, meaning it reinvests 0% of its operating cash flow (€186.97 Million) in capital expenditures (€44.48 Million). See 2TZ net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Capital Reinvestment Ratio (2013–2025)
This chart tracks Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's Capital Reinvestment Ratio across 12 annual periods. Check Tianjin Zhong Xin Pharmaceutical Group C cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
Year-by-year Capital Reinvestment Ratio for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. For live market cap and broader valuation context, see how much is Tianjin Zhong Xin Pharmaceutical Group C worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €461.07 Million | €118.61 Million | ▲ +101.9% |
| 2024 | 0.13x | €924.67 Million | €117.81 Million | ▼ -37.8% |
| 2023 | 0.20x | €688.49 Million | €140.93 Million | ▲ +28.5% |
| 2022 | 0.16x | €677.25 Million | €107.90 Million | ▼ -13.5% |
| 2021 | 0.18x | €852.40 Million | €156.95 Million | ▼ -34.6% |
| 2020 | 0.28x | €671.42 Million | €189.16 Million | ▼ -32.1% |
| 2019 | 0.41x | €495.49 Million | €205.61 Million | ▼ -17.4% |
| 2018 | 0.50x | €350.14 Million | €175.81 Million | ▲ +80.5% |
| 2016 | 0.28x | €417.77 Million | €116.20 Million | ▲ +8.3% |
| 2015 | 0.26x | €360.58 Million | €92.64 Million | ▲ +5.1% |
| 2014 | 0.24x | €286.85 Million | €70.15 Million | ▼ -27.9% |
| 2013 | 0.34x | €213.44 Million | €72.42 Million | — |